
Founded in 2019 by Vivek Ganesh, PhD and Jay Shah, PhD and with the addition of Trevor Meyer, PhD, Neurava's mission is to develop and deliver breakthrough wearable technology that can fundamentally transform outcomes in areas of unmet clinical need, beginning with epilepsy. Leveraging a deep background in neuromodulation and epilepsy, we have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Our AI-powered wearable platform is a novel approach aiming to monitor the entire continuum beginning with seizures and any induced cardiorespiratory dysfunctions, to ultimately mitigate the risk of SUDEP and provide peace of mind to families and individuals living with epilepsy.
Prior to this role, Jay earned his PhD in Electrical Engineering from Purdue University, where he led a collaborative team of physicians and engineers to develop a closed-loop, implantable device for treating glaucoma, leveraging an application-specific integrated circuit (ASIC) that he designed to achieve this functionality. Concurrently, he worked at Bionode Inc., a medical device startup in ophthalmology, where he led clinical studies and product development to advance the company’s novel contact lens system delivering electroceutical therapy for glaucoma toward commercialization. Earlier in his career, Jay was part of the R&D team at Cyberonics (now LivaNova) in Houston, TX, contributing to ensuring the company’s neuromodulation system for treating epilepsy met updated standards for MRI-induced heating. He received a B.S. in Biomedical Engineering from The University of Texas at Austin.
Prior to this role, Vivek earned his PhD in Electrical Engineering from Purdue University, where he developed a closed-loop implantable electroceutical device to monitor gastric electrophysiological signals in both chronic and acute models. He led product development and delivered on an ambitious technology roadmap in a highly collaborative team of scientists, electrophysiologists and physicians at major institutions like the Florey Institute in Melbourne. Earlier in his career, Vivek worked at a cutting edge diagnostic technology startup, overseeing the launch of its flagship single-photon based product to pilot customers. Vivek also worked in the Health Technologies team at Apple Inc. in Cupertino, contributing to the development of new hardware and health features of the Series 1 Apple Watch. He received a B.S. in Biomedical Engineering and a minor in Electrical Engineering from Purdue University.
Prior to this role, Trevor earned his Ph.D. in Electrical Engineering from Johns Hopkins University where he focused on signal processing and machine learning, including developing novel deep learning architectures for seizure prediction and implementing them on low-power implantable device platforms. Additionally, he worked on multimodal analysis methods in Parkinson's and Alzheimer's disease patients, as well as novel functional imaging during vagus nerve stimulation. Prior to this role, he worked in the Health Technologies team at Apple Inc. on new Apple Watch hardware and health features, as well as at other large and small MedTech companies. Through his career, Trevor has gained extensive experience in physiological signal processing, with a focus on customized analysis of biomedical signals in real-time systems. He received a B.S. in Biomedical Engineering from Purdue University.
Prior to this role, Dan was CEO of Cyberonics, leading the company through a transformative period, successfully growing revenues from approximately $100 million to $300 million while advancing neuromodulation devices for epilepsy. Following the merger of Cyberonics and Sorin, Moore continued his leadership as Chairman of LivaNova, where he further expanded the company's epilepsy neuromodulation business. He brings over 35 years of experience in medical devices, with a strong focus on epilepsy treatment. He received his MBA from Boston University, and his B.A. from Harvard University.
Prior to this role, Jed was an operating partner of Elevate Ventures and has worked with numerous healthcare startups helping navigate complex reimbursement strategies and sales processes. He spent 16 years at Eli Lilly, leading a global team through internal and external cross-functional partnerships to develop and deliver core data, platforms, policies, and processes for customer-facing initiatives in 100+ affiliates. His deep understanding of market access and commercialization will be pivotal in driving Neurava's growth and market position. He received his MBA from Harvard University, and his B.S. in Mechanical Engineering from Purdue University.
Prior to this role, Mona was a member of Life Science Angels with over 20 years of leadership experience in healthcare, life sciences & biotech. She has a proven track record in strategic planning, business development, raising capital, introducing Innovative & disruptive technologies from concept to launch, successful global commercialization and managing operations across various life science companies. She received her M.S. in Microbiology from Columbia University.
A novel approach years in the making
Jun 2019
Founding
Building on the discovery of a potential mechanism of action behind SUDEP in Dr. Pedro Irazoqui’s lab at Purdue, Neurava was founded and spun out of Purdue by then-graduate students Jay and Vivek with a mission to mitigate the risk of SUDEP.
Jan 2020
First investment
Neurava received its first investment from Elevate Ventures to build on its pre-clinical data and develop its MVP
Mar 2021
FDA pre-submission meeting
Neurava conducts its first FDA pre-submission meeting to introduce A1 to FDA and clarify its regulatory pathway
Sep 2021
Pre-seed round closed
Neurava closed an oversubscribed pre-seed round of $656,250 led by Elevate Ventures and secured its first strategic investment from epilepsy leaders UCB to develop a first-gen MVP and validate this on people with epilepsy
May 2022
Neurava enrolls its first adult patient with epilepsy
After several months in R&D, Neurava begins its first usability study to validate A1’s ability to detect convulsive seizures against clinical gold standard and enrolls its first patient
May 2022
A1 records its first convulsive seizure
A huge moment of pride for the Neurava team. We successfully capture a first convulsive seizure with positive usability scores
Jul 2022
A1 captures a near-SUDEP seizure
A1 successfully captures a convulsive seizure, which induces a cardiorespiratory collapse in the patient and is classified as near-SUDEP.
Apr 2023
Neurava finishes its first usability study
A1 successfully captures multiple seizures with positive usability scores, and captured data can now be used to develop a seizure detection algorithm to improve the state of the art
Nov 2023
Seed round closed
Neurava closes an oversubscribed seed round of $2.26M led by Life Science Angels, with a second follow on investment from existing partners UCB, to complete clinical validation of A1 and N1 in adults and children with epilepsy, and pursue FDA regulatory clearances for A1
Jan 2024
Second usability study begins
Neurava begins its final usability study in adults and children with epilepsy at 6 centers, to validate A1 and N1 against reference data collected in the EMU
Feb 2024
N1 captures its first seizure-induced cardiorespiratory dysfunction
Another milestone for our team, N1 successfully captures seizure-induced cardiorespiratory dysfunctions in a patient
Feb 2024
Neurava enrolls its first pediatric patient
One step closer to bringing our platform to not only adults but children ages 6+ with epilepsy
Oct 2024
First publication
A near-SUDEP case study was published in 'Epileptic Disorders', emphasizing the need for cardiorespiratory and seizure monitoring in people with epilepsy
Nov 2024
FDA pre-submission meeting
Neurava conducts a second FDA pre-submission meeting to introduce N1 to FDA and clarify its regulatory pathway
Our Investors





Subscribe to get our updates
Get in Touch
Are you impacted by epilepsy, a healthcare professional, a researcher, an innovator, a company, or an investor seeking breakthrough medical technology? Let's connect!
contactAddress
HQ: 101 W Dickman St
Suite 807
Baltimore, MD 21230
Information
Follow Us
© Neurava Inc. 2025 All Rights Reserved
designed & built by arcxne